Germany · Delayed Price · Currency is EUR NovaBridge Biosciences Company Description
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States.
The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors.
It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor.
The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab.
The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025.
NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
| Country | Cayman Islands |
| Founded | 2014 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 32 |
| CEO | Xi-Yong Fu |
Contact Details
Address: 2440 Research Boulevard Rockville, 20850 United States | |
| Phone | 240 745 6330 |
| Website | novabridge.com |
Stock Details
| Ticker Symbol | 0VY |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Xi-Yong Fu | Chief Executive Officer |
| Kyler Lei | Chief Financial Officer |
| Tyler Ehler | Head of Investor Relations |